MALT1
49 programs · 48 companies
Programs
49
Companies
48
Active Trials
29
Targeting MALT1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | NMOSD | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | Urothelial CaHS | |
| GSK-6516 | GSK | Phase 1/2 | MesoCervical Ca | |
| BII-5240 | Biogen | Phase 2/3 | Wet AMDHNSCC | |
| ALN-3958 | Alnylam | Phase 2 | PNH | |
| Cevisacituzumab | Alnylam | Preclinical | RBMCL | |
| ION-8812 | Ionis | Phase 1 | Prostate CaAS | |
| RLA-8772 | Relay Therapeutics | Phase 2 | PAH | |
| MGN-5438 | MacroGenics | Phase 1/2 | Pancreatic Ca | |
| Pemilemzoparlimab | Astellas | Phase 1/2 | TTR Amyloidosis | |
| 452-670 | Eisai | Approved | Cervical Ca | |
| Polalucimab | Jiangsu Hengrui | Phase 3 | CML | |
| CIP-2846 | Cipla | Phase 3 | WMAS | |
| PEK-IIT-150 | Peking Univ Cancer Hosp | Phase 1 | CML | |
| Adagracapivasertib | Affinia Ther | Approved | PompeDravet | |
| Darasacituzumab | Lyell Immuno | Phase 1 | CSUCLL | |
| Riboglumide | Onconova | Phase 2 | Epilepsy | |
| Capibrutinib | BioAtla | Phase 3 | Alzheimer's | |
| VND-7068 | Vanda Pharma | Phase 2 | Gastric CaPBC | |
| Kemafotisoran | CStone Pharma | Phase 3 | OCD | |
| SIE-6456 | Sierra Oncology (GSK) | Phase 2 | CML | |
| Doxazanubrutinib | Proteus Digital | Phase 3 | FabryRCC | |
| CON-372 | Concert Pharma (Sun) | Approved | NarcolepsyThymoma | |
| Surainavolisib | Ascentage | NDA/BLA | BCC | |
| Nidatuximab | Transcenta | Preclinical | GBMMyelofibrosis | |
| Pemivorutinib | InveniAI | NDA/BLA | PSPPNH | |
| Suraglumide | Quanta Ther | Phase 1 | Pompe | |
| Ribotuximab | Remix Ther | Phase 1 | WMCSU | |
| IVE-1720 | Iveric (Astellas) | Phase 2/3 | WilmsSCLC | |
| Doxatenlimab | Clearside Bio | Phase 3 | Parkinson'sMG | |
| Talalemzoparlimab | Aldel Bio | Approved | UC | |
| DCP-2468 | Deciphera | Preclinical | PsoriasisMG | |
| Zenoderotide | Cara Ther | Phase 1/2 | EoE | |
| 418-9392 | Mitsubishi Tanabe | NDA/BLA | Hemophilia AOvarian Ca | |
| Rilurelsin | Sosei Heptares | Phase 1 | Crohn's | |
| Olpasertib | Daewoong Pharma | Phase 2 | RCCCRC | |
| YB-3858 | Y-Biologics | Preclinical | MM | |
| Sotoglumide | 4D Pharma | Phase 2/3 | ObesityRSV | |
| Miriosocimab | Chiesi | Phase 3 | MG | |
| FYB-2633 | Formycon | Phase 1 | Alzheimer'sIPF | |
| BCA-6126 | Biocartis | Phase 2/3 | ALS | |
| Tiranesiran | Eurofarma | Preclinical | Wet AMDNB | |
| TEV-5361 | Teva Pharma | Preclinical | RBCTCL | |
| PRI-IIT-117 | Princess Margaret | Preclinical | Bladder Ca | |
| NAT-IIT-836 | Natl Taiwan Univ Hosp | NDA/BLA | Asthma | |
| SIR-IIT-898 | Siriraj Hospital | Phase 3 | Rett | |
| A-3864 | Agilent Technologies | NDA/BLA | PNH | |
| Fixatenlimab | Synlogic | NDA/BLA | Prostate CaMeso | |
| Tixalucimab | Cellid | Phase 1/2 | CML |